承董事會命 布魯可集團有限公司 朱偉松先生 董 事 長、執 行 董 事 兼 首 席 執 行 官 香 港，二 零 二 五 年 八 月 十 二 日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Bloks Group Limited 布魯可集團有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：0325） 董事會會議通告 布魯可集團有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於二零二五年八月二十二日（星 期 五）舉 行，藉 以（其 中 包 括）批准本公司及 其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 未 經 審 計 中 期 業 績。 截 至 本 公 告 日 期，董 事 會 包 括：執 行 董 事 朱 偉 松 先 生 及 盛 曉 峰 先 生；非 執 行 董 事 常 凱 斯 ...

Investment Rating - The report maintains a positive outlook on the IP derivatives industry, indicating a new round of investment opportunities due to rising IP popularity and market trends [6][8]. Core Insights - Sanrio's Q1 FY 2026 results show total revenue, operating profit, and net profit attributable to shareholders increased by 49%, 88%, and 38% respectively, driven by the growing popularity of Sanrio characters globally and increased foot traffic in domestic stores and theme parks [3][8]. - The company has raised its FY 2026 earnings forecast, with total sales, operating profit, and net profit for the first half of the fiscal year adjusted to 836 billion yen, 350 billion yen, and 247 billion yen, reflecting increases of 33%, 48%, and 29% respectively [8]. - Sanrio's strategic initiatives include leveraging "evergreen" IPs, expanding its IP matrix, and pursuing globalization to mitigate cyclical risks and ensure stable growth [8]. Summary by Sections Financial Performance - For the period of April to June 2025, Sanrio's revenue growth was attributed to the increasing global appeal of its characters and the influx of both foreign tourists and domestic customers to its stores and theme parks [3][8]. - Revenue growth by region includes Japan (38%), Europe (200%), North America (23%), Latin America (89%), and Asia (85%), with operating profit growth in the same regions being 58%, 529%, 133%, 106%, and 133% respectively [8]. Strategic Initiatives - Sanrio is focusing on enhancing its IP derivatives through events like the 50th anniversary of Melody and the 20th anniversary of Kuromi, alongside the launch of new content on platforms like Netflix [8]. - The company aims to strengthen its licensing model globally and improve profitability through data-driven product selection and brand collaborations [8]. Market Outlook - The report expresses optimism for the IP derivatives sector, highlighting recent successful events and the potential for continued product launches and content development [8]. - The report notes that the recent market corrections have likely absorbed pessimistic expectations, and companies with strong IP management and product innovation capabilities are expected to maintain long-term growth [8].

Investment Rating - The industry investment rating is "Outperform the Market" [2][11]. Core Insights - Sanrio has raised its performance targets, with Q1 FY26 revenue reaching 43.1 billion JPY, a year-on-year increase of 49.1%. Operating profit was 20.2 billion JPY, up 88%, and net profit attributable to shareholders was 14.2 billion JPY, an increase of 37.8% [4]. - The company has adjusted its full-year revenue target from 162.2 billion JPY (up 12% YoY) to 168.8 billion JPY (up 16.5%), and its operating profit target from 60 billion JPY (up 16%) to 67.3 billion JPY (up 30%) [4]. - The global IP economy continues to show high prosperity, with significant growth in sales and licensing businesses driven by increased tourist numbers and high-value collaborations in Japan [4]. Summary by Sections Financial Performance - Q1 FY26 results: Revenue of 43.1 billion JPY (+49.1% YoY), Operating profit of 20.2 billion JPY (+88%), Net profit of 14.2 billion JPY (+37.8%) [4]. - Japan's revenue reached 24.4 billion JPY (+38.1%), with operating profit at 12.1 billion JPY (+57.9%) [4]. - Asia's revenue was 10 billion JPY (+84.8%), with operating profit at 5.7 billion JPY (+132.8%) [4]. - North America generated revenue of 5.7 billion JPY (+23.1%), with operating profit at 2.7 billion JPY (+133.4%) [4]. Strategic Outlook - Sanrio aims for a long-term market value of 5 trillion JPY (approximately 240 billion CNY) in ten years, which is more than three times its current market value of about 1.6 trillion JPY [4]. - The growth strategy focuses on licensing as the core business, alongside new ventures in digital content development [4]. Investment Recommendations - The report suggests monitoring companies such as Blokus, Morning Glory, Guobo Co., and Chuangyuan Co. for their potential in the IP economy and related sectors [4].

Investment Rating - The report indicates a positive investment outlook for the IP toy sector, paper industry, and home furnishing sector, highlighting specific companies to watch [2][4][17]. Core Insights - The IP toy market continues to thrive, with Sanrio's FY26Q1 performance exceeding expectations, driven by strong IP character sales, particularly Hello Kitty, across various regions [2][4]. - The paper industry is entering a peak demand season in Q3, with expectations for price stabilization and potential upward movement due to supply-side improvements [14][15]. - The home furnishing sector is poised for recovery as Beijing relaxes housing purchase restrictions, which may enhance valuation and stimulate demand [17][19]. Summary by Sections 1. IP Toy Sector - Sanrio's FY26Q1 revenue reached 431 billion JPY, a 49% year-on-year increase, with operating profit up 88% and net profit up 38%, attributed to strong IP character performance [2][4]. - Companies such as Morning Glory, Chuangyuan, Chaohongji, Guobo, and Blucor are highlighted for their innovative IP collaborations and product launches [2][4][6][9][10]. 2. Paper Industry - The report notes that Q3 demand is gradually increasing, with expectations for paper prices to stabilize and potentially rise, supported by reduced production from overseas suppliers [14][15]. - Key companies to monitor include Sun Paper, Nine Dragons, and Bohui Paper, as they are positioned to benefit from the improving supply-demand dynamics [14][15]. 3. Home Furnishing Sector - The easing of purchase restrictions in Beijing is expected to boost the home furnishing sector, with companies like Sophia, Oppein, Gujia, and others identified as having strong dividend safety margins [17][19][23]. - The report emphasizes the potential for valuation recovery in the home furnishing sector, driven by improved consumer confidence and demand from the secondary housing market [19][23].

Core Insights - Zhonghui Biotech-B (HK02627) successfully listed on the Hong Kong Stock Exchange on August 11, 2023, with an opening price of HKD 33.0 per share, marking a significant increase of 157.98% by the end of the trading day [1][5]. Company Overview - Zhonghui Biotech was established in 2015 and focuses on the research, manufacturing, and commercialization of innovative vaccines, utilizing new technological methods for traditional vaccines [3]. - The company has a product pipeline that includes two core products and 11 other vaccines under development. The core product "Hui Er Kang Xin" is the first and only approved quadrivalent influenza virus subunit vaccine in China [4]. Financial Performance - The company's revenue is entirely derived from the sales of "Hui Er Kang Xin," with reported revenues of RMB 52.168 million in 2023, RMB 260.612 million in 2024, and RMB 41.3 million in the first quarter of 2025 [7][8]. - The company incurred losses of RMB 424.741 million, RMB 258.716 million, and RMB 63.331 million during the respective reporting periods [8]. Market Dynamics - The company experienced an oversubscription of over 4000 times during its IPO, attracting significant interest from investors, with a total subscription amount exceeding HKD 200 billion [5]. - The influenza vaccine market in China has grown from RMB 2 billion in 2019 to an expected RMB 7 billion in 2024, with a compound annual growth rate of 28.7% [10]. Product Pricing and Sales - "Hui Er Kang Xin" is priced at HKD 319 per dose, which is higher than the industry average. The average bidding price for influenza vaccines in China has decreased from HKD 126 in 2022 to HKD 125 in 2023, with further declines expected [10]. - The company noted that the sales of its vaccine are seasonal, with sales concentrated from July to September, and faced challenges such as product returns amounting to RMB 21.3 million in 2023 [10]. Use of Proceeds - The funds raised from the IPO will be allocated to the development and registration of core products, development of other vaccines, enhancement of production and commercialization capabilities, working capital, and the development of various technological platforms [11].

Core Viewpoint - The debut of Zhonghui Biotech on the Hong Kong stock market has set a record for the highest first-day gain of a new stock since 2025, with a closing increase of 157.98% on August 11 [1]. Group 1: Company Overview - Zhonghui Biotech, established in 2015, focuses on the research, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [4]. - The company has two core products: a quadrivalent influenza virus subunit vaccine approved for individuals aged three and above, and a freeze-dried human rabies vaccine currently under development [4][6]. - Zhonghui Biotech has 11 other vaccines in development, targeting various diseases with significant vaccination demand [4]. Group 2: IPO Performance - The IPO of Zhonghui Biotech was highly successful, achieving over 4000 times oversubscription, with total subscription amounts exceeding 200 billion HKD, making it the "super subscription king" of the Hong Kong biotech sector this year [4][5]. - The public offering in Hong Kong accounted for only 11.95% of the total shares available, with the remaining 88.05% allocated to international institutional investors [4][6]. Group 3: Financial Performance - Zhonghui Biotech has not yet achieved profitability and continues to invest heavily in research and development [6]. - The company's projected revenues for 2023, 2024, and the first quarter of 2025 are 52 million RMB, 260 million RMB, and 41.3 million RMB, respectively, with corresponding net losses of 425 million RMB, 259 million RMB, and 87 million RMB [6][7]. - The company anticipates continued net losses in 2025 due to significant expected expenditures in research, sales, and administration [9]. Group 4: Investment and Valuation - Zhonghui Biotech has completed three rounds of financing, raising nearly 1 billion RMB, with its valuation increasing from 746 million RMB to 4.189 billion RMB [10][15]. - The current market capitalization of Zhonghui Biotech exceeds 13 billion RMB, with early investors, such as Gao Tejia, seeing substantial returns on their investments [12][14].

Core Viewpoint - The article highlights the remarkable debut performance of Zhonghui Biotech on the Hong Kong stock market, achieving a first-day increase of 157.98%, marking the highest debut gain for a new stock since 2025 [1]. Group 1: Company Overview - Zhonghui Biotech, established in 2015, focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [6]. - The company has two core products: a quadrivalent influenza virus subunit vaccine approved in May 2023 for individuals aged three and above, and a lyophilized human rabies vaccine currently under development [6][9]. - Zhonghui Biotech has 11 other vaccines in the pipeline, targeting various diseases with significant vaccination demand [6]. Group 2: IPO Performance - The IPO of Zhonghui Biotech was oversubscribed by over 4,000 times, with total subscription amounts exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong biotech sector this year [6][7]. - The public offering accounted for only 11.95% of the total shares available, with the remaining 88.05% allocated to institutional investors [6][8]. Group 3: Financial Performance - Zhonghui Biotech has not yet achieved profitability and continues to invest heavily in research and development [9]. - The company's projected revenues for 2023, 2024, and the first quarter of 2025 are 52 million RMB, 260 million RMB, and 413,000 RMB, respectively, with corresponding net losses of 425 million RMB, 259 million RMB, and 87 million RMB [9][10]. - The company anticipates continued net losses in 2025 due to significant expected R&D, sales, and administrative expenses [12]. Group 4: Investment and Valuation - Zhonghui Biotech has completed three rounds of financing, raising nearly 1 billion RMB, with its valuation increasing from 746 million RMB to 4.189 billion RMB [19]. - The current market capitalization of Zhonghui Biotech exceeds 13 billion HKD, with early investors, such as Gao Tejia, seeing substantial returns on their investments [19][16].

Core Viewpoint - The article discusses the recent IPO of Zhonghui Biotech, highlighting its significant oversubscription and the company's current financial status, including its ongoing losses and investment in R&D. Company Overview - Zhonghui Biotech, established in 2015, focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [3][6]. - The company has two core products: a quadrivalent influenza virus subunit vaccine approved in May 2023 and a developing lyophilized human rabies vaccine [3][6]. IPO Details - Zhonghui Biotech's IPO was highly successful, with over 4000 times oversubscription and total subscription amount exceeding 200 billion HKD, making it the "super subscription king" in the Hong Kong biotech sector for 2023 [3][4]. - The public offering accounted for only 11.95% of the total shares, with the remaining 88.05% allocated to institutional investors [3][5]. Financial Performance - The company has not yet achieved profitability, with projected revenues of 52 million RMB, 260 million RMB, and 413,000 RMB for 2023, 2024, and Q1 2025, respectively [6][9]. - Net losses are expected to be 425 million RMB, 259 million RMB, and 87 million RMB for the same periods, with R&D expenditures of 283 million RMB, 206 million RMB, and 47 million RMB [6][9]. Market Position and Challenges - Zhonghui Biotech's quadrivalent influenza vaccine is the first and only approved in China, but it is more expensive than other types of influenza vaccines, which may affect market acceptance [6][9]. - The pricing of the second-class vaccines is market-driven, and high bid prices could lead to losing contracts, impacting sales and financial performance [8][9]. Investment and Valuation - The company has completed three rounds of financing, raising nearly 1 billion RMB, with its valuation increasing from 746 million RMB to 4.189 billion RMB [10][15]. - Following the IPO, the total market capitalization of Zhonghui Biotech has exceeded 13 billion HKD, benefiting early investors significantly [10][15].

Investment Rating - The report maintains an "Outperform" rating for the industry [3] Core Insights - Suzano announced a price increase of $20 per ton for commodity pulp in the Asian market for August, indicating a potential recovery in pulp and paper prices from current cyclical lows [2][4] - The report highlights the ongoing price adjustments in the paper industry, with various paper types experiencing different price movements, suggesting a recovery trend driven by supply-demand dynamics [4][50] - The report emphasizes the importance of policy catalysts in the home furnishing sector, particularly in light of recent housing policy optimizations in Beijing [4][31] Summary by Sections Home Furnishing - Recent policy changes in Beijing allow families to purchase multiple properties outside the city center, which is expected to stimulate the housing market [4][31] - Major home furnishing companies are currently valued at historical lows, presenting potential investment opportunities as market sentiment improves [4][31] Paper Industry - As of August 8, 2025, various paper prices are reported: double glue paper at 4993.75 CNY/ton (unchanged), copper plate paper at 5320 CNY/ton (unchanged), white card paper at 3955 CNY/ton (down 35 CNY/ton), box board paper at 3463.4 CNY/ton (up 12.8 CNY/ton), and corrugated paper at 2582.5 CNY/ton (up 46.25 CNY/ton) [4][50] - The report notes that the current pulp and paper prices are at cyclical lows, with expectations for a rebound due to supply-demand imbalances [4][50] Consumer Goods - The report discusses the launch of new health-focused products in the personal care sector, indicating a shift towards higher quality and compliance with health standards [4][6] - The collaboration between Morning Glory stationery and popular anime IPs is expected to enhance brand visibility and sales [4][6] Export Chain - In July, China's total exports increased by 7.2% year-on-year, with significant growth in exports to ASEAN countries [4][6] - The report suggests that the ongoing shift of production capacity to Southeast Asia may enhance the long-term competitiveness of companies with overseas supply chain layouts [4][6] Packaging - New regulations in Shanghai aimed at reducing single-use plastics are expected to drive demand for recyclable and biodegradable packaging solutions [4][6] - The report recommends companies involved in eco-friendly packaging solutions as potential investment opportunities [4][6] New Tobacco Products - The introduction of new electronic cigarette products in the UK is anticipated to boost market share for refillable devices [4][6] - The report highlights the potential for growth in the new tobacco sector, particularly for companies with strong partnerships and product offerings [4][6] Textile and Apparel - The textile and apparel sector has shown resilience, with notable increases in revenue for key players despite some challenges [4][6] - The report identifies leading companies in the apparel sector as potential investment opportunities based on their performance [4][6]

Core Viewpoint - LEGO, founded in 1932, has become one of the largest toy manufacturers globally, effectively navigating economic cycles due to its resonance across various aspects such as market, users, ecosystem, and operations, providing valuable insights for the development of similar companies like Blokus [1][3]. Summary by Sections Company Overview - LEGO's revenue for 2024 is projected at 74.3 billion Danish Kroner, approximately 83.8 billion RMB, reflecting a year-on-year increase of 13%. The net profit is expected to be 13.8 billion Danish Kroner, around 15.6 billion RMB, with a year-on-year growth of 5% [2]. Development Stages - The development of LEGO can be categorized into several phases: 1. **Foundation Stage (1932-1957)**: Establishment of plastic bricks and initial overseas achievements. 2. **Global Expansion (1958-1978)**: Patent for brick coupling solved, leading to accelerated globalization, though later hindered by the oil crisis. 3. **Rapid Growth (1979-1994)**: Sales surged, product matrix expanded, and embraced technological changes, particularly in North America. 4. **Adjustment Phase (1995-2004)**: Faced issues of over-expansion and cash flow loss, with IP collaborations (e.g., Star Wars) playing a crucial role. 5. **Fast Development (2005-Present)**: Focused on core business, supply chain reforms, IP collaborations, and expanding adult and female customer segments [2][3]. Key Success Factors - LEGO's ability to navigate economic cycles is attributed to: 1. **Product Innovation**: Continuous innovation in the brick segment, with a global market growth rate of 11% from 2019 to 2023, and a total of over 840 product offerings expected in 2024 [3]. 2. **User Base Expansion**: Increasing sales of 18+ sets to 15% in 2024 and development of products targeting female consumers [3]. 3. **Ecosystem Development**: Initiation of IP collaborations in 1999 with the Star Wars series, leading to synergistic growth across video games, movies, and theme parks [3]. 4. **Geographical and Channel Expansion**: As of 2024, LEGO operates 5 factories, 4 regional distribution centers, and 1,069 stores globally [3]. 5. **Fan Economy Operations**: Platforms like LEGO Ideas and BrickLink facilitate fan engagement and commercialization [3]. Challenges Faced - LEGO has encountered several challenges: 1. **Patent Expiration**: Loss of market share due to patent expirations, leading to a renewed focus on product development and patent applications [3]. 2. **Aggressive Expansion**: The aggressive expansion in the late 90s necessitated a shift towards a more focused strategy, emphasizing synergy between new and core businesses [3]. 3. **Outsourced Production Issues**: Quality issues with outsourced production led to a return to in-house manufacturing, ensuring superior mold precision [3].